Sanofi S.A., FR0000120578

Sanofi stock after-hours at EUR 70.68: plus 0.21 percent

Published on 10/06/2026 at 18:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock was at EUR 70.68 after-hours at 6:31 p.m. CEST on October 6, 2026, up 0.21 percent versus the prior close at Lang & Schwarz. Sanofi said Q3 results are due October 30.

Architectural visualization render of a futuristic pharmaceutical laboratory building with cleanroom airlocks, floor-to-ceiling glass walls and violet-blue accent lighting
Sanofi FR0000120578 architectural CGI render of multi-story high-tech pharmaceutical laboratory with cleanroom airlock entry, Illustration mit AI erstellt.

Sanofi stock was at EUR 70.68 after-hours at 6:31 p.m. CEST on October 6, 2026, up 0.21 percent versus the prior close of EUR 70.53 at Lang & Schwarz.

Sanofi trading in Germany

The Lang & Schwarz price was EUR 70.68 at 6:31 p.m. CEST, compared with the prior close of EUR 70.53. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Sanofi stock.

Third-quarter results scheduled for October 30

Sanofi announced on October 6 that its aide-mémoire for third-quarter 2026 results was available on the company’s investor website. The document covers non-comparable items, foreign-currency impact and share count. Sanofi said it will publish its third-quarter 2026 results on October 30, 2026. Sanofi’s press release provides the schedule.

Expanded antibody collaboration with Regeneron

In a separate October 1 announcement, Sanofi and Regeneron said they had expanded their antibody collaboration to include four long-acting antibodies. Regeneron is to receive an upfront payment of $1 billion, with potential additional development, regulatory and commercial milestone payments of up to $7 billion. The companies said they will share development and commercialization costs and split future profits from the potential products equally. Sanofi’s announcement said Regeneron will lead research and development, while Sanofi will lead global commercial efforts.

Disclaimer...

en | FR0000120578 | SANOFI S.A. | boerse | 70244748 | bgmi